Core Insights - Hyperion DeFi has announced a strategic partnership with Felix to utilize 500,000 HYPE for launching a custom on-chain perpetual futures market, marking a significant advancement in decentralized finance [1][2][3] Group 1: Partnership and Product Development - The HYPE Asset Use Service (HAUS) agreement allows Hyperion DeFi to support Felix in managing a new market using the HIP-3 framework, which facilitates the creation of markets for non-crypto assets [2][3] - This partnership is expected to expand Hyperliquid's product offerings and user base while generating new revenue streams from staked HYPE assets [3][4] Group 2: Market Performance and Future Plans - Felix has achieved a total value locked (TVL) of over $1 billion as of September 2025, indicating strong market traction [4][11] - Felix plans to further integrate its DeFi infrastructure into the development of Felix Exchange, aiming to enhance liquidity access and stablecoin minting [4][5] Group 3: Hyperliquid Platform and HYPE Token - Hyperliquid is a next-generation blockchain designed for high-frequency trading, featuring on-chain perpetual futures and spot order books with rapid transaction times [6] - The HYPE token serves as the native currency of Hyperliquid, with over 30 million HYPE autonomously purchased and sequestered by the blockchain as of October 2025 [7][8]

New lighting technology delivers full-spectrum, Far Red, and UV light beneath canopy to increase yield, boost flavor, enhance aroma, and improve overall flower quality for commercial cultivatorsDENVER, Oct. 29, 2025 (GLOBE NEWSWIRE) -- GrowGeneration Corp. (NASDAQ: GRWG) (“GrowGen” or the “Company”), the nation’s largest specialty hydroponic and organic gardening retailer, today announced the launch of its Dialed In™ Tri-Spec Under Canopy Light, a first-of-its-kind lighting solution engineered to boost lowe ...

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [1][4] - The company will be represented by its Founder, President, and CEO, Laxminarayan Bhat, at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, in New York City [1] Company Overview - Reviva's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [4] - The company has been granted composition of matter patents for both drug candidates in the United States, Europe, and several other countries [4] Conference Details - The Spartan Capital Securities conference will feature over 60 selected companies across various sectors, including technology, healthcare, and consumer [2] - More than 500 institutional and high-net-worth investors are expected to attend, providing opportunities for dialogue between growth companies and the investment community [2]

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Wednesday, November 5, 2025, at 8:30 a.m. EST to report its third quarter 2025 financial results and recent corporate highlights. To particip ...

Core Insights - Belite Bio Inc is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with significant unmet medical needs [3] Group 1: Company Overview - Belite Bio is advancing therapeutics targeting conditions such as STGD1 and GA in advanced dry AMD, as well as specific metabolic diseases [3] - The company's lead candidate, Tinlarebant, is an oral therapy aimed at reducing bisretinoid toxin accumulation in the eye [3] - Tinlarebant is currently being evaluated in multiple studies: a Phase 3 study (DRAGON), a Phase 2/3 study (DRAGON II) for adolescent STGD1 subjects, and a Phase 3 study (PHOENIX) for subjects with GA [3] Group 2: Upcoming Events - The executive management team will present at the Deutsche Bank ADR Virtual Investor Conference on November 4, 2025, at 10:30 am ET [1] - A webcast of the presentation will be available on the conference website, with a replay accessible for 90 days post-presentation [2]

MONTREAL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Harfang Exploration Inc. (TSX-V: HAR) (“Harfang”) and SOQUEM Inc. (“SOQUEM” and together the “Companies”) announce multiple high-grade gold discoveries from their joint summer 2025 exploration program at Harfang’s wholly-owned Menarik West Property (the “Property”), located in Eeyou Istchee James Bay, Québec (see Figure 1). HIGHLIGHTS Discovery of six (6) gold showings, two (2) gold and silver showings, and one (1) copper showing.Top three grab samples returned 55 ...

Core Insights - CHAR Technologies Ltd. has been invited to join the Canadian Iron & Steel Energy Research Association (CISERA) for the 2025–2026 term, marking it as the first biocarbon producer in the organization [1][2] - CISERA focuses on advancing net zero and decarbonized iron and steelmaking, with notable members including ArcelorMittal Dofasco GP and Stelco Inc. [2] - CHAR Tech will contribute its expertise in high-temperature pyrolysis and renewable biocarbon production to support the development of alternative reductants and renewable fuels for commercial steel operations [3][4] Company Involvement - The participation in CISERA aligns with the company's mission to accelerate industrial decarbonization through scalable solutions, enhancing collaboration with key players in the iron and steel sector [4] - Through this involvement, CHAR Tech aims to strengthen connections across the iron and steel value chain, promoting renewable biocarbon as a key element in sustainable production [4] About CISERA - CISERA is a not-for-profit organization established in 1965, supporting research and development for Canada's steel and metallurgical coal producers, with a goal of achieving net-zero emissions in steel production by 2050 [5] - The majority of CISERA-sponsored research is conducted at the Metallurgical Fuels Laboratory, which is equipped for advanced modeling and pilot-scale investigations [6] About CHAR Technologies - CHAR Technologies utilizes high-temperature pyrolysis technology to process unmerchantable wood and organic waste, generating renewable natural gas or green hydrogen and a solid biocarbon that serves as a carbon-neutral alternative to metallurgical coal [6][7] - The company's technology aligns with the global green energy transition by diverting waste from landfills and producing sustainable clean energy for heavy industry decarbonization [7]

Core Viewpoint - Oxford Square Capital Corp. is set to discuss its third quarter 2025 earnings in a conference call scheduled for November 4, 2025, at 9:00 AM Eastern time [1] Company Overview - Oxford Square Capital Corp. is a publicly-traded business development company that primarily invests in syndicated bank loans and, to a lesser extent, in debt and equity tranches of collateralized loan obligation (CLO) vehicles [2] - The company also engages in CLO investments that may include warehouse facilities, which are financing structures designed to aggregate loans for the formation of CLO vehicles [2]

Core Insights - Paris Hilton collaborates with Collegium Pharmaceutical to share her ADHD journey and encourage others to seek treatment [3][5][6] - ADHD affects approximately 15.5 million adults and 6.5 million children in the U.S., with an estimated 70% of adults experiencing symptoms into adulthood [4] Company Overview - Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions, particularly in pain management and neuropsychiatry [16][17] - The company’s leading product, JORNAY PM, is a treatment for ADHD that is taken at night and lasts throughout the day [6][7] Product Information - JORNAY PM is indicated for the treatment of ADHD in patients aged 6 years and older, helping to increase attention and decrease impulsiveness and hyperactivity [7] - The medication contains methylphenidate and is classified as a federally controlled substance due to its potential for abuse [8][9] Treatment Journey - Paris Hilton was diagnosed with ADHD as a young adult and has since worked with her healthcare provider to find an effective treatment plan, ultimately choosing JORNAY PM [6][5] - The collaboration aims to raise awareness about ADHD and the importance of finding suitable treatment options [3][5]

Core Insights - Zscaler has introduced new innovations in its Zscaler Digital Experience™ (ZDX™) that enhance enterprise productivity by enabling faster issue detection and resolution, achieving a 98% reduction in issue detection time and resolving issues in minutes [1][2][3] Group 1: ZDX Innovations - The new ZDX features provide end-to-end visibility and control, allowing enterprises to resolve issues quickly, thus minimizing downtime and enhancing user productivity [3] - ZDX unifies device, network, and application telemetry to facilitate rapid root-cause identification, addressing the estimated $400 billion annual losses from digital downtime [2][3] - The innovations include Network Intelligence, which identifies ISP bottlenecks and reroutes traffic to ensure fast connectivity, and Zscaler Managed Monitoring, which provides 24/7 monitoring of critical applications [6] Group 2: Market Positioning - Zscaler is positioned to meet the evolving demands of a dynamic, distributed, and AI-first world by consolidating security and networking functions through its globally distributed, multi-tenant cloud [3] - The shift from fragmented point solutions to unified platforms is highlighted as a key trend, with Zscaler leveraging AI to enhance user experience and accelerate issue resolution [3] Group 3: Operational Benefits - The new features allow organizations to monitor device health and performance, proactively addressing widespread issues, extending device lifecycles, and reducing hardware refresh costs [6] - By holding service providers accountable and ensuring compliance with SLAs, organizations can secure compensation and negotiate better terms, further enhancing productivity [6]